Paroxysmal supraventricular tachycardia (PSVT) is a type of supraventricular tachycardia. Often people have no symptoms. Otherwise symptoms may include palpitations, feeling lightheaded, sweating, shortness of breath, and chest pain. Episodes start and end suddenly.
About 2.3 per 1000 people have paroxysmal supraventricular tachycardia. Problems typically begin in those 12 to 45 years old. Women are more often affected than men. Outcomes in those who otherwise have a normal heart are generally good. An ultrasound of the heart may be done to rule out underlying heart problems.

Market Analysis and Insights: Global Paroxysmal Supraventricular Tachycardia Market
The global Paroxysmal Supraventricular Tachycardia market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Paroxysmal Supraventricular Tachycardia market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Paroxysmal Supraventricular Tachycardia market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Paroxysmal Supraventricular Tachycardia market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Paroxysmal Supraventricular Tachycardia market.

Global Paroxysmal Supraventricular Tachycardia Scope and Market Size
Paroxysmal Supraventricular Tachycardia market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Paroxysmal Supraventricular Tachycardia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Diagnosis and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Diagnosis
EPS
Echocardiogram
Holter Monitor
Others

Segment by Application
Hospital
Specialty Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Sanofi
Pfizer
Novartis International
Teva Pharmaceutical Industries
Medtronic
Glenmark Pharmaceuticals
Abbott
Boston Scientific